Best Practices for Successful Execution of Radiopharmaceutical Clinical Trials

Prior to joining PPD in 2015, Dr. Nguyen was VP, Clinical Development at Endocyte, Chief Medical Officer at Tigris Pharmaceutical and Executive Medical Director at Eli Lilly and Co. He also was a Medical Fellow at the Investigational Drug Branch, Cancer Treatment Evaluation Program, NCI, NIH, and Medical Reviewer for INDs and NDAs at the US Food and Drug Administration prior to joining the industry.

Dr. Nguyen holds an MD from the University of Maryland School of Medicine and a PhD in Organic Chemistry from Georgetown University in Washington, DC. He completed an oncology fellowship at the NCI, NIH.

Read Less...

This includes more than two decades on the sponsor side and over five years in a Contract Research Organization (CRO), managing projects from First-In-Human Phase I through to global Phase III and post-marketing Phase IV studies.

Their expertise is particularly pronounced in hematology/oncology, where they have worked with radiolabeled compounds, immunotherapy, antibody-drug conjugates (ADCs) and medical imaging studies. Additionally, they have experience in autoimmune disorders and imaging studies. Notably, they played a pivotal role in the development and approval of the first ADC for triple-negative breast cancer, demonstrating their capacity to lead critical projects from initial human trials to full regulatory approval.

As a leader, she is hands-on and driven, known for her excellent communication skills and high integrity. She excels in taking full ownership of studies, effectively motivating and mentoring teams to deliver projects on time and within budget. This background makes them an invaluable leader in the field of clinical research, particularly within drug development for oncology and complex therapeutic areas.

Read Less...